- Home
- TLSA
as of 09-15-2026 3:42pm EST
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
| Founded: | 2013 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 145.1M | IPO Year: | 2017 |
| Target Price: | N/A | AVG Volume (30 days): | 687.3K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $0.87 - $2.35 | Next Earning Date: | 05-04-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Stock Insider Trading Activity of Tiziana Life Sciences Ltd. (TLSA)
Chief Executive Officer
Avg Cost/Share
$1.00
Shares
237,616
Total Value
$237,616.00
Owned After
4,793,684
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$0.97
Shares
83,807
Total Value
$81,292.79
Owned After
4,793,684
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$1.00
Shares
667,000
Total Value
$667,000.00
Owned After
4,793,684
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Elrifi Ivor | TLSA | Chief Executive Officer | Aug 5, 2026 | Buy | $1.00 | 237,616 | $237,616.00 | 4,793,684 | |
| Elrifi Ivor | TLSA | Chief Executive Officer | Aug 4, 2026 | Buy | $0.97 | 83,807 | $81,292.79 | 4,793,684 | |
| Elrifi Ivor | TLSA | Chief Executive Officer | Aug 3, 2026 | Buy | $1.00 | 667,000 | $667,000.00 | 4,793,684 |
Compare TLSA vs Leading Stocks
See how TLSA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TLSA Tiziana Life Sciences Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.